Welcome, please login

Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Sub-Clinical Atrial Fibrillation.

© 2025 Population Health Research Institute
Unauthorized use of this system is strictly prohibited. Your IP 192.168.175.44

ARTESiA: A randomized, parallel group, double-blind, Phase IV, multicenter, prospective trial of apixaban versus aspirin to reduce the risk of stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation.
(NCT01938248; EudraCT 2014-001397-33)